The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas-Reference-Cited by-同舟云学术

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas

Published:2016-05-31 Issue:1 Volume:35 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Wang Hao-Yuan,Tang Kai,Liang Ting-Yu,Zhang Wei-Zhong,Li Ji-Ye,Wang Wen,Hu Hui-Min,Li Ming-Yang,Wang Hui-Qing,He Xiao-Zheng,Zhu Zhi-Yuan,Liu Yan-Wei,Zhang Shi-Zhong

Funder

Guangdong Provincial Clinical Medical Centre for Neurosurgery

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13046-016-0362-7

Reference24 articles.

1. De Carli E, Wang X, Puget S. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:2248. author reply 2249.

2. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32:3091–100.

3. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28:2348–55.

4. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334–43.

5. Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki N. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol. 2011;178:1395–402.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of RNA methylation in glioma: Mechanisms, prognostic biomarkers, and therapeutic targets;Cellular Signalling;2024-12

2. Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives;Cancers;2024-08-02

3. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-05

4. Clinical and imaging characteristics of supratentorial glioma with IDH2 mutation;Neuroradiology;2024-04-24

5. Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma;Acta Neuropathologica Communications;2023-11-27